Evidence map›Paper›PMID 28777374›Full record

ArticleCell death and differentiation2017

High mobility group A1 protein modulates autophagy in cancer cells.

Andrea Conte, Simona Paladino, Gaia Bianco, Dominga Fasano, Raffaele Gerlini, Mara Tornincasa, Maurizio Renna, Alfredo Fusco, Donatella Tramontano, Giovanna Maria Pierantoni

Open access · hybridAbstract read
In one paragraph

Article in Cell death and differentiation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Review
  4. The role of HMGA1 in genome stability: Implications in human cancer.Cellular and molecular life sciences : CMLS · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Andrea ConteDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II' and Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS) of CNR, Naples, Italy.
Simona PaladinoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II' and Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS) of CNR, Naples, Italy.
Gaia BiancoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II' and Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS) of CNR, Naples, Italy.
Dominga FasanoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II' and Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS) of CNR, Naples, Italy.
Raffaele GerliniDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II' and Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS) of CNR, Naples, Italy.
Mara TornincasaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II' and Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS) of CNR, Naples, Italy.
Maurizio RennaDepartment of Medical Genetics, Cambridge Institute for Medical Research, Wellcome Trust, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Alfredo FuscoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II' and Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS) of CNR, Naples, Italy.
Donatella TramontanoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II' and Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS) of CNR, Naples, Italy.
Giovanna Maria PierantoniDepartment of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II' and Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS) of CNR, Naples, Italy.
University of Naples Federico II · ITInstitute for Experimental Endocrinology and Oncology · ITWellcome Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High Mobility Group A1 (HMGA1) is an architectural chromatin protein whose overexpression is a feature of malignant neoplasias with a causal role in cancer initiation and progression. HMGA1 promotes tumor growth by several mechanisms, including increase of cell proliferation and survival, impairment of DNA repair and induction of chromosome instability. Autophagy is a self-degradative process that, by providing energy sources and removing damaged organelles and misfolded proteins, allows cell survival under stress conditions. On the other hand, hyper-activated autophagy can lead to non-apoptotic programmed cell death. Autophagy deregulation is a common feature of cancer cells in which has a complex role, showing either an oncogenic or tumor suppressor activity, depending on cellular context and tumor stage. Here, we report that depletion of HMGA1 perturbs autophagy by different mechanisms. HMGA1-knockdown increases autophagosome formation by constraining the activity of the mTOR pathway, a major regulator of autophagy, and transcriptionally upregulating the autophagy-initiating kinase Unc-51-like kinase 1 (ULK1). Consistently, functional experiments demonstrate that HMGA1 binds ULK1 promoter region and negatively regulates its transcription. On the other hand, the increase in autophagosomes is not associated to a proportionate increase in their maturation. Overall, the effects of HMGA1 depletion on autophagy are associated to a decrease in cell proliferation and ultimately impact on cancer cells viability. Importantly, silencing of ULK1 prevents the effects of HMGA1-knockdown on cellular proliferation, viability and autophagic activity, highlighting how these effects are, at least in part, mediated by ULK1. Interestingly, this phenomenon is not restricted to skin cancer cells, as similar results have been observed also in HeLa cells silenced for HMGA1. Taken together, these results clearly indicate HMGA1 as a key regulator of the autophagic pathway in cancer cells, thus suggesting a novel mechanism through which HMGA1 can contribute to cancer progression.

Indexed as

AutophagyAnimalsAutophagy-Related Protein-1 HomologAutophagy-Related Protein 5Cell ProliferationCell SurvivalGene Knockdown TechniquesGene SilencingGreen Fluorescent ProteinsHeLa CellsHMGA1a ProteinHumansIntracellular Signaling Peptides and ProteinsMiceMicrotubule-Associated ProteinsNeoplasmsATG5 protein, humanAutophagy-Related Protein-1 HomologAutophagy-Related Protein 5Green Fluorescent ProteinsHMGA1a ProteinIntracellular Signaling Peptides and ProteinsMAP1LC3A protein, humanMicrotubule-Associated ProteinsProtein Serine-Threonine KinasesULK1 protein, humanUlk2 protein, human

Identifiers

PMID28777374
PMCPMC5635219
OpenAlexW2744196903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.